<?xml version="1.0" encoding="big5"?><rss version="2.0"><channel><link>https://www.wearn.com</link><description> 投資人的好朋友 </description><language> zh-tw </language><copyright> 聚財資訊股份有限公司 版權所有 All Rights Reserved </copyright><image><title>聚財網 wearn.com</title><link>https://www.wearn.com</link><url>https://www.wearn.com/images/logo_2018_300.png</url></image><lastBuildDate>2026/11/14 上午 07:19:29</lastBuildDate><title>國邑* 6875｜財經新聞｜聚財網 </title><item><title><![CDATA[國邑L606合作夥伴調整開發策略 擴增全球樞紐性試驗]]></title><link><![CDATA[https://news.wearn.com/c2143622.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-11-11T09:20:04+08:00]]></pubDate></item><item><title><![CDATA[授權夥伴訴訟和解  國邑*：L606三期臨床試驗持續推進]]></title><link><![CDATA[https://news.wearn.com/c2126143.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-10-15T18:00:03+08:00]]></pubDate></item><item><title><![CDATA[國邑合作夥伴專利訴訟和解 L606三期臨床持續推進]]></title><link><![CDATA[https://news.wearn.com/c2125919.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-10-15T14:44:56+08:00]]></pubDate></item><item><title><![CDATA[折疊面板8成江山轉向書本式　蘋果、三星、華為分食市場大餅]]></title><link><![CDATA[https://news.wearn.com/c2111216.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-09-22T02:09:51+08:00]]></pubDate></item><item><title><![CDATA[焦點股》國邑*：新藥核准進入美國臨床二期試驗]]></title><link><![CDATA[https://news.wearn.com/c2110619.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-09-21T10:11:37+08:00]]></pubDate></item><item><title><![CDATA[國邑*硬皮症指端潰瘍新劑型新藥 獲美國FDA核准進行二期臨床試驗]]></title><link><![CDATA[https://news.wearn.com/c2109297.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-09-18T18:24:48+08:00]]></pubDate></item><item><title><![CDATA[國邑長效吸入新藥L608 獲美國FDA核准二期臨床 要克服硬皮症指端潰瘍]]></title><link><![CDATA[https://news.wearn.com/c2109274.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-09-18T17:54:12+08:00]]></pubDate></item><item><title><![CDATA[國邑*長效吸入型新藥 啟動中國臨床三期試驗]]></title><link><![CDATA[https://news.wearn.com/c2107190.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-09-16T09:54:51+08:00]]></pubDate></item><item><title><![CDATA[國邑吸入型新藥 L606 獲准中國執行全球三期樞紐試驗]]></title><link><![CDATA[https://news.wearn.com/c2107149.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-09-16T08:40:12+08:00]]></pubDate></item><item><title><![CDATA[國邑授權夥伴 Liquidia 逐步增加 L606投入 加速全球三期Re-Spire收案]]></title><link><![CDATA[https://news.wearn.com/c2072199.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-08-14T14:02:18+08:00]]></pubDate></item><item><title><![CDATA[國邑呼吸裝置 獲許可證]]></title><link><![CDATA[https://news.wearn.com/c2061590.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-08-04T22:50:56+08:00]]></pubDate></item><item><title><![CDATA[國邑旗下普元生技「邑普能」獲 TFDA 醫材許可 完成藥械合一重要拼圖]]></title><link><![CDATA[https://news.wearn.com/c2060882.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-08-04T09:25:44+08:00]]></pubDate></item><item><title><![CDATA[國邑併普元 拚藥械合一]]></title><link><![CDATA[https://news.wearn.com/c2060655.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-08-04T00:44:08+08:00]]></pubDate></item><item><title><![CDATA[國邑併購普元生技 打造藥械合一雙平台新局 提升全球授權、商業化實力]]></title><link><![CDATA[https://news.wearn.com/c2059812.html]]></link><description><![CDATA[]]></description><pubDate><![CDATA[2026-08-03T08:46:43+08:00]]></pubDate></item></channel></rss>